| Date | Title | Description | |
|---|---|---|---|
| 26 Jul 2023 | On P&L | The Company releases the first half 2023 financial results presentation | Download |
| 26 Jul 2023 | On buy-back programmes | The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program. | Download |
| 10 May 2023 | On P&L | The Company releases the first quarter 2023 financial results presentation | Download |
| 10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
| 25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 May 2025 | On business and financial situation | The Company releases the first three months 2025 financial results presentation | Download |
| 08 May 2025 | Announcement of General Shareholders’ Meeting | The Company announces the call of its 2025 Ordinary General Shareholders' Meeting | Download |
| 08 May 2025 | On business and financial situation | ROVI informs on the award of a grant in its favor to develop the R&D Project IPCEI - ROVI (LAISOLID) | Download |
| 04 Apr 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2025 | Download |
| 25 Feb 2025 | Annual Financial Reports and Audit Reports | The Company submits the 2024 Annual Financial Report | Download |